Quarter Horse study tracks inherited disease alleles across lines
Bottom line
A new JAVMA study tracked allele frequencies for seven inherited disorders in American Quarter Horses from 2020 through 2024, comparing elite performance subgroups with a random cohort. The disorders included hyperkalemic periodic paralysis, type 1 polysaccharide storage myopathy, malignant hyperthermia, myosin-heavy chain myopathy, glycogen branching enzyme deficiency, hereditary equine regional dermal asthenia, and equine juvenile spinocerebellar ataxia. The paper builds on earlier work showing that disease-allele burden can vary sharply by discipline in Quarter Horses, and it arrives as breed and laboratory resources continue to expand around panel-based testing for Quarter Horses and related breeds. (hero.epa.gov)
Why it matters: For equine veterinarians, the study is less about any single mutation than about risk stratification in a heavily substructured breed. Prior research found markedly higher frequencies of HYPP and PSSM1 in halter lines, HERDA in cutting lines, and lower frequencies in racing and barrel racing groups, underscoring why breed-level averages can miss discipline-specific risk. Today’s testing landscape also covers MYHM and EJSCA alongside the older AQHA panel diseases, which gives clinicians more tools for breeding counseling, pre-purchase discussions, neonatal workups, anesthesia planning, and management of muscle and skin disease in Quarter Horses and related breeds. (hero.epa.gov)
What to watch: Watch for follow-up discussion on whether the 2020–2024 data show meaningful declines in long-monitored alleles, and whether newer additions such as MYHM and EJSCA reshape routine testing recommendations in specific performance lines. (escholarship.org)
Key facts
- Study type
- JAVMA study
- Species
- American Quarter Horses
- Study period
- 2020 through 2024
- Design
- Compared elite performance cohorts with a random sample population
- Disorders studied
- HYPP, PSSM1, MH, MYHM, GBED, HERDA, and EJSCA
- Main focus
- Allele frequencies for inherited disorders
- Context
- Builds on earlier work showing discipline-specific disease-allele burden in Quarter Horses
- Testing landscape
- Panel-based testing now includes MYHM and EJSCA alongside older AQHA panel diseases
A new study in the Journal of the American Veterinary Medical Association examined allele frequencies for seven inherited disorders in American Quarter Horses between 2020 and 2024, comparing elite performance cohorts with a random sample population. The disorders were HYPP, PSSM1, MH, MYHM, GBED, HERDA, and EJSCA, giving the paper a broader scope than older Quarter Horse surveys that focused on five disorders before MYHM and EJSCA were added to the conversation. (escholarship.org)
That broader scope matters because Quarter Horses are not one genetically uniform population. A 2009 JAVMA study found clear differences by discipline, with halter horses carrying significantly higher allele frequencies for HYPP and PSSM, cutting horses standing out for HERDA, western pleasure horses for GBED, and racing and barrel racing groups showing the lowest frequencies among the diseases studied. Those findings helped establish the idea that performance subgroups function almost like distinct risk pools inside the same breed. (hero.epa.gov)
The new 2020–2024 paper also reflects how the testing environment has changed. UC Davis’ Veterinary Genetics Laboratory now markets a Quarter Horse and related breeds disease panel that includes GBED, HERDA, HYPP, MYHM, MH, and PSSM1, and notes that AQHA-linked horses may still need registry-specific ordering and recording. AAEP’s updated 2024 position statement likewise lists HYPP, MH, MYHM, and PSSM1 among dominant or codominant disorders, and EJSCA, GBED, and HERDA among recessive conditions for which validated commercial testing is available. (vgl.ucdavis.edu)
EJSCA is an especially important addition to the screening landscape. The disease was first described after cases observed in 2020, and a 2024 Journal of Veterinary Internal Medicine report characterized it as a rapidly progressive, uniformly fatal neurologic disease of Quarter Horse foals younger than 1 month. Brown’s 2025 UC Davis thesis frames the new JAVMA allele-frequency work as part of a larger effort to move from mutation discovery to population screening, suggesting the field is shifting from identifying rare syndromes to measuring how widely those variants are distributed in breeding populations. (pubmed.ncbi.nlm.nih.gov)
There’s also added clinical nuance around MYHM. In a UC Davis VGL summary of prior research, the MYH1 mutation was described as dominant with variable penetrance, with one client-supported study finding the mutation in 29% of the study population and reporting that about 80% of homozygous horses and 20% of heterozygous horses in the surveyed group developed muscle atrophy or severe stiffness. That kind of incomplete penetrance is exactly why updated prevalence data matter in practice: a positive genotype does not map neatly to a predictable clinical course, but it still changes breeding and management conversations. (vgl.ucdavis.edu)
Why it matters: For veterinary professionals, the practical takeaway is that population surveillance helps sharpen case-level decision-making. Discipline-specific allele frequencies can inform which tests to prioritize in a weak foal, a horse with recurrent tying-up, unexplained muscle atrophy, suspicious skin fragility, or a breeding consultation involving popular bloodlines. The data also support more precise counseling for pet parents and breeders, especially when discussing dominant conditions such as HYPP or PSSM1 versus recessive risks such as GBED, HERDA, and EJSCA, or the variable penetrance seen with MYHM. (hero.epa.gov)
The study may also be a useful barometer for whether longstanding testing programs are changing the breed’s inherited disease burden. AQHA’s testing infrastructure and educational resources have expanded over time, and MYHM was added to AQHA-related panel testing in recent years. If the new paper shows declines in some historically monitored alleles but persistence in certain performance lines, that would reinforce a familiar lesson in veterinary genetics: access to testing alone doesn’t eliminate risk unless breeding behavior changes with it. That last point is an inference based on the history of Quarter Horse subgroup differences and the expansion of available testing. (vgl.vetmed.ucdavis.edu)
What to watch: The next question is whether breed organizations, laboratories, and equine clinicians use these 2020–2024 data to refine subgroup-specific screening advice, especially for newer panel targets such as EJSCA and for clinically messy disorders such as MYHM, where genotype, trigger exposure, and phenotype don’t always line up cleanly. (vgl.ucdavis.edu)